Key Takeaways
- Sector: Consumer.
- Geography: United Kingdom.
Analysis
L’Oréal has announced the acquisition of a majority stake in British skincare brand Medik8, a move aimed at strengthening its position in the rapidly growing dermocosmetics market. The deal, estimated to value Medik8 at approximately €1 billion, underscores L’Oréal’s commitment to expanding its portfolio of science-backed skincare products.
Founded in 2009 by scientist Elliot Isaacs, Medik8 has gained recognition for its innovative formulations, particularly its vitamin A-based anti-aging products. The brand's flagship product, Crystal Retinal, has achieved cult status among skincare enthusiasts. With a presence in Europe and the United States, Medik8 has successfully scaled through an omni-channel retail model while maintaining a focus on professional skincare innovation.
As part of the transaction, Inflexion, the private equity firm that previously backed Medik8, will retain a minority stake. The brand’s founder and current management team will remain in place to ensure continuity and support future growth. L’Oréal has also secured rights to buy out the remaining stake in the future.
“This is an exciting day for Medik8,” said CEO Simon Coble. “I am delighted to be joining forces with a company that shares our vision for the brand’s future growth and whose core values align with our deep commitment to science, innovation, and results without compromise.”
Cyril Chapuy, President of L’Oréal Luxe, commented, “Medik8 perfectly complements our skincare portfolio. We share a strong belief in its global potential and are excited to build a powerful brand presence worldwide.”
The acquisition is expected to close in the coming months, subject to regulatory approvals and customary conditions.